Allen Operations’s Ginkgo Bioworks DNA Stock Holding History

Allen Operations’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$614K	Hold	61,951	–	–	0.09%	30
2026 Q1	$380K	Hold	61,951	–	–	0.06%	35
2025 Q4	$515K	Hold	61,951	–	–	0.06%	35
2025 Q3	$903K	Hold	61,951	–	–	0.11%	34
2025 Q2	$697K	Hold	61,951	–	–	0.1%	31
2025 Q1	$353K	Hold	61,951	–	–	0.06%	29
2024 Q4	$608K	Sell	61,951 -3	-0%	-$26	0.1%	29
2024 Q3	$505K	Buy	61,954 +2	+0%	+$20	0.09%	30
2024 Q2	$828K	Hold	61,952	–	–	0.16%	26
2024 Q1	$2.87M	Hold	61,952	–	–	0.55%	22
2023 Q4	$4.19M	Hold	61,952	–	–	0.83%	21
2023 Q3	$4.49M	Hold	61,952	–	–	0.99%	22
2023 Q2	$4.61M	Hold	61,952	–	–	1.02%	21
2023 Q1	$3.3M	Hold	61,952	–	–	0.84%	22
2022 Q4	$4.19M	Buy	61,952 +5,727	+10%	+$527K	1.12%	19
2022 Q3	$7.02M	Hold	56,225	–	–	1.87%	16
2022 Q2	$5.35M	Hold	56,225	–	–	1.35%	18
2022 Q1	$9.06M	Hold	56,225	–	–	1.6%	19
2021 Q4	$18.7M	Buy	56,225 +1,638	+3%	+$778K	2.6%	16
2021 Q3	$25.3M	Buy	+54,587	New	+$26.6M	3.92%	10

Other funds holding DNA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JMFC

J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

Allen Operations's DNA Position: Q2 2026 in Review

Allen Operations held its Ginkgo Bioworks (DNA) position steady in Q2 2026 at 61,951 shares worth $614K. The position accounts for 0.09% of the portfolio, ranked #30.

Allen Operations first reported a position in DNA in Q3 2021 and has held it in 20 quarters since. The position peaked at $25.3M in Q3 2021. 183 funds tracked by Wall St. Rank hold DNA as of Q2 2026.

Allen Operations held 61,951 shares of Ginkgo Bioworks worth $614K as of Q2 2026.
Allen Operations left its Ginkgo Bioworks share count unchanged in Q2 2026.
Ginkgo Bioworks made up 0.09% of Allen Operations's portfolio in Q2 2026, its #30 holding.
Allen Operations first reported a position in Ginkgo Bioworks in Q3 2021 and has held it in 20 quarters since.
Allen Operations's Ginkgo Bioworks position peaked at $25.3M in Q3 2021.
183 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2026.

Based on Allen Operations's 13F filing for Q2 2026, filed 5 Aug 2026.